An open study with reversible MAO-A inhibitors in complicated Parkinson's disease.
Ruggieri
S
S
Mediterranean Institute of Neuroscience, Sanatrix, Pozzilli (IS), Italy.
Fabbrini
G
G
Bramante
L
L
DePandis
F
F
Stocchi
F
F
Barbanti
P
P
Vacca
L
L
Manfredi
M
M
D000978:Antiparkinson Agents / Q000627:therapeutic use; D001549:Benzamides / Q000009:adverse effects / Q000627:therapeutic use*; D018491:Dopamine Agonists / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use; D008875:Middle Aged; D020912:Moclobemide; D008996:Monoamine Oxidase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D009069:Movement Disorders / Q000188:drug therapy / Q000209:etiology; D010300:Parkinson Disease / Q000150:complications / Q000188:drug therapy*
D000978:Antiparkinson Agents; D001549:Benzamides; D018491:Dopamine Agonists; D008996:Monoamine Oxidase Inhibitors; D007980:Levodopa; D020912:Moclobemide